Recent scientific developments in medicine have the potential to cure or fundamentally modify previously incurable or poorly treated diseases and conditions, relieving the suffering of patients and ...

Much of the biopharmaceutical industry this week is focused on the J.P. Morgan Healthcare Conference (JPM), where business leaders are investing in science and technologies with the potential to ...

Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making. The ICER perspective on what value means ...

BOSTON, MA - JUNE 6, 2019: Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), talks with chief medical officer David Rind during a meeting at their offices in Boston. ...

This article is part of a Health Affairs Forefront short series, “Enhancing Value By Evaluating Health Care Services.” The series discusses ways to extend the use of tools for clinical and economic ...

Trying to gauge the value of new drugs and devices is becoming increasingly important in the U.S. health care system, something that other countries have done explicitly for years. Pressure to get ...

To ensure that value assessment accounts for patient needs, we need a better understanding of the outcomes that are most important to patients, write authors from COVIA Health Solutions and the ...